Secukinumab is approved for use among patients with enthesitis-related arthritis (ERA) aged 4 years and up, and those with psoriatic arthritis (PsA) who are at least 2 years old.
The FDA has approved secukinumab (Cosentyx from Novartis) for children and adolescents with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).
The decision is based on results of the phase 3 JUNIPERA trial, which found the treatment yielded reduced flare risk in this patient population compared with placebo. Over 2 years, researchers also observed improved disease activity in patients treated with secukinumab, while safety was consistent with the treatment’s known profile among those with plaque psoriasis, PsA, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.
The 2-year randomized withdrawal trial enrolled 86 pediatric patients aged 2 to 17 diagnosed with ERA or juvenile PsA (JPsA). Both ERA and JPsA are characterized by joint swelling, while, if left untreated, the conditions can lead to high levels of pain and disability.
Secukinumab can now be administered to patients with ERA aged 4 years and older or patients with PsA who are at least 2 years old. The approved dosing, administered via a subcutaneous injection every 4 weeks following loading doses, is 75 mg (body weight: 15 kg to < 50 kg) or 150 mg (≥ 50 kg). With correct guidance from a health care provider, it can be administered outside a provider’s office by an adult caregiver.
The treatment now has a total of 5 indications, and the latest approval means it is the first biologic indicated for ERA. It is also the only treatment approved for both ERA and PsA in pediatric US patients. Earlier this year, secukinumab was approved as a first-line treatment for pediatric psoriasis.
Secukinumab, a fully human biologic, functions by inhibiting interleukin-17A.
The primary end point of JUNIPERA was time to flare in treatment period 2 (week 12 to 104). Investigators found:
“The symptoms of PsA and ERA can be debilitating for children and adolescents living with these chronic conditions, impacting their daily lives," Tiffany Westrich-Robertson, CEO, International Foundation for Autoimmune & Autoinflammatory Arthritis, said in a statement. "It is encouraging to see an additional treatment option for these underserved patient populations."
Patients taking secukinumab can experience new cases of inflammatory bowel disease and serious allergic reactions.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More